Partner

Worldwide Plaza, 825 Eighth Avenue
New York, NY 10019

+1 212 474 1257

40 & Under Hot List

Future Star


Practice area:

Commercial
Competition/antitrust
M&A disputes
Securities


Rory A. Leraris is a partner in Cravath’s Litigation Department. Her practice focuses on antitrust, M&A, securities and derivative litigation, and other complex commercial disputes. 


Ms. Leraris obtained a major victory for American Express before the U.S. Supreme Court in an antitrust lawsuit originally brought by the DOJ and 17 state attorneys general challenging certain provisions in AmEx’s merchant agreements—one of the most significant government antitrust enforcement actions in recent history. She also represented AmEx in a series of putative class actions and individual lawsuits brought by large supermarket and pharmacy chains in New York federal court alleging that American Express imposed rules that limited merchants from steering their customers to other payment methods, which settled following AmEx’s victory in the Supreme Court. Ms. Leraris continues to represent AmEx in a putative class action alleging that AmEx tied acceptance of certain of its card products to acceptance of other card products in violation of the Sherman Act. 


Ms. Leraris also represented Sabre in its successful appeal to the Second Circuit of an adverse jury verdict in a lawsuit brought by US Airways in New York federal court alleging that Sabre used its monopoly power to charge inflated fees to airlines for bookings. In September 2019, the Second Circuit vacated the jury verdict and remanded for further proceedings. 


Ms. Leraris currently represents members of the special transaction committee of Viacom’s board of directors in consolidated putative class action litigation alleging that those directors breached their fiduciary duties in connection with Viacom’s $30 billion merger with CBS. She is also representing Viatris and certain of the company’s directors and officers in securities fraud class action litigation regarding the company’s classification of the EpiPen under the Medicaid Drug Rebate Program, and Palantir Technologies in a Delaware Superior Court action alleging intentional interference with a proposed deal to sell $60 million of Palantir stock. 


Ms. Leraris received a B.A. magna cum laude in Psychology and Sociology from Amherst College in 2003 and a J.D. from the University of Chicago Law School in 2008. Ms. Leraris joined Cravath in 2008 and was elected a partner in 2016. 


Updated July 2021